Stocktoria
Chemomab Therapeutics Ltd. CMMB
Chemomab Therapeutics Ltd. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D expense | $5.8M | $11.3M | $18.4M | $17.0M | $6.3M | $4.7M | $13.3M | $7.5M |
| Operating income | -$112.0M | -$103.0M | — | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | -$534,000 | $0 | $0 | $0 | $306,000 |
| Net income | -$9.0M | -$13.9M | -$24.2M | -$27.6M | -$12.5M | -$6.0M | -$27.1M | -$13.8M |
| EPS (diluted) | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | — | — | — |
| Operating cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M | -$5.2M | -$16.5M | -$14.2M |
| Free cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.6M | -$5.3M | -$16.6M | -$14.4M |
| Cash & equivalents | $7.6M | $6.1M | $9.3M | $13.5M | $15.2M | $11.7M | $17.6M | $7.5M |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M |
| Total liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M | $1.7M | $4.8M | $3.0M |
| Shareholders' equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| EPS growth | -53.8% | -62.1% | -14.9% | +101.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.